Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Has results × Priapism × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Breast Neoplasms 1301 Neoplasms 953 Carcinoma, Non-Small-Cell Lung 774 Prostatic Neoplasms 695 Multiple Myeloma 504 Colorectal Neoplasms 466 Lung Neoplasms 428 Leukemia, Myeloid, Acute 427 Neoplasm Metastasis 408 Lymphoma 398 Melanoma 394 Leukemia 351 Lymphoma, Non-Hodgkin 345 Leukemia, Lymphocytic, Chronic, B-Cell 317 Ovarian Neoplasms 311 Pancreatic Neoplasms 304 Precursor Cell Lymphoblastic Leukemia-Lymphoma 283 Recurrence 272 Head and Neck Neoplasms 258 Lymphoma, Follicular 255 Myelodysplastic Syndromes 242 Glioblastoma 240 Carcinoma, Renal Cell 240 Brain Neoplasms 234 Hodgkin Disease 220 Lymphoma, Large B-Cell, Diffuse 216 Carcinoma, Hepatocellular 216 Lymphoma, Mantle-Cell 193 Sarcoma 180 Stomach Neoplasms 178

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01895361 2020-01-31

SUSTAIN

Reprixys Pharmaceutical Corporation

Phase 2 Completed

198 enrolled 18 charts 1 FDA

Classical hematology

Anemia, Sickle Cell, Priapism

Data powered by HemOnc (CC BY 4.0) Colophon ⚡